Binge eating disorder

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
월요일, 5월 6, 2024
Shift, Migraine, FDA, Agitation, Research, EMERGE, Webcast, CNS, Prescription, Reboxetine, Privacy, Medicine, BED, Obstructive sleep apnea, Fibromyalgia, Shift work, Deficit spending, Food, Sleep, System, ADHD, SWD, SYMPHONY, NT1, Therapy, Quality of life, Food and Drug Administration, MDD, Narcolepsy Network, Shirin David, Patient, Somnolence, FOCUS, Safety, Depression, CGRP, Binge eating disorder, Medicare, Cataplexy, Central nervous system, Government, DSM-IV codes, Clinical trial, EDS, NDA, NMDA, GPO, Psychiatry, MD, Idiopathic hypersomnia, Smoking, CMAI, Pivotal, Breakthrough therapy, Growth, Pharmaceutical industry

Auvelity net product sales were $53.4 million for the first quarter of 2024, representing 240% year-over-year growth.

Key Points: 
  • Auvelity net product sales were $53.4 million for the first quarter of 2024, representing 240% year-over-year growth.
  • Total cost of revenue was $6.3 million for the first quarter of 2024.
  • Research and development (R&D) expenses were $36.8 million for the first quarter of 2024, compared to $17.8 million for the comparable period in 2023, respectively.
  • Approximately 95,000 prescriptions were written for Auvelity in the first quarter of 2024, representing a 12% sequential increase versus the fourth quarter of 2023.

EDCare Brings Virtual Eating Disorder Treatment Services to Colorado, Kansas, and Nebraska

Retrieved on: 
화요일, 4월 30, 2024
Argyreia nervosa, LPC, Congressional Research Service, Telehealth, Housing, Insurance, IOP, Eating disorder, Intensive outpatient program, Mental health, Eating, Food, Helsinki University Central Hospital, PHP, COVID-19, Binge eating disorder, Nursing

DENVER, April 30, 2024 /PRNewswire/ -- EDCare, a leading provider of eating disorder treatment services, announced the expansion of its treatment options in Colorado, Kansas, and Nebraska to include a Virtual Intensive Outpatient Program (IOP).

Key Points: 
  • DENVER, April 30, 2024 /PRNewswire/ -- EDCare, a leading provider of eating disorder treatment services, announced the expansion of its treatment options in Colorado, Kansas, and Nebraska to include a Virtual Intensive Outpatient Program (IOP).
  • The virtual program offers flexible support that seamlessly integrates into individuals' busy schedules, providing evidence-based eating disorder treatment from the comfort of one's own homes.
  • Only about 20 percent of individuals with eating disorders are able to access treatment (Hart et al., 2011).
  • EDCare is in-network with most major insurance companies, including Colorado Medicaid and TRICARE®, and offers affordable housing accommodations for those seeking in-person treatment.

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Retrieved on: 
월요일, 4월 1, 2024
Central nervous system, Binge eating disorder, Patient, CNS, BED, Therapy, Safety, Pharmaceutical industry

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults.

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults.
  • ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of BED in adults.
  • Approximately 450 patients will be randomized in a 1:1:1 ratio to receive solriamfetol (150 or 300 mg) or placebo for 12 weeks.
  • The first patient was screened in the ENGAGE trial in March 2024.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Retrieved on: 
목요일, 3월 21, 2024
MGH, Eating, Obesity, Oxytocin, Patient, Weight loss, Binge eating disorder, University, Prader–Willi syndrome, Tonix Pharmaceuticals, IND, American Chemical Society, Magnesium, Adolescence, Insulin resistance, Hospital, Safety, ACS, Social anxiety disorder, Spectrum, Pain, Nasal administration, Poster

CHATHAM, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announces a poster presentation at the American Chemistry Society (ACS) Spring 2024 Meeting, held March 17-21, 2024, in New Orleans, Louisiana. A copy of the poster is available under the scientific presentations page of the Tonix website at www.tonixpharma.com.

Key Points: 
  • A copy of the poster is available under the scientific presentations page of the Tonix website at www.tonixpharma.com .
  • The poster presentation titled, Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations, describes the discovery and characterization of novel oxytocin analogues that are candidate treatments for craniofacial pain, excessive eating (including Prader Willi Syndrome), and endocrinological conditions including bone health in autism and insulin resistance.
  • “Intranasal oxytocin has several potential therapeutic applications,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • The Phase 2 ‘STROBE’ study at MGH is investigating the efficacy and safety of TNX-1900 as a novel therapeutic agent to reduce binge eating frequency in adults with binge-eating disorder.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
화요일, 2월 20, 2024
Shift, Acquisition, DSM-IV codes, Fibromyalgia, Central nervous system, Total, New Drug Application, MD, Narcolepsy, FDA, Marketing, Smoking, Food, Somnolence, Growth, SYMPHONY, Reboxetine, Psychiatry, Dextromethorphan/bupropion, Migraine, FOCUS, Safety, Therapy, Medicare, NMDA, CNS, Food and Drug Administration, BED, Webcast, Depression, Binge eating disorder, Patient, Agitation, Shirin David, Medicaid, SWD, Breakthrough therapy, MDD, NDA, Prescription, Pharmaceutical industry

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

Monte Nido & Affiliates Provides Education on Binge Eating Disorder for National Eating Disorders Awareness Week

Retrieved on: 
화요일, 2월 13, 2024
Binge eating disorder, Eating, Doctor of Philosophy, Weight loss, Body image, Argyreia nervosa, MBA, Food, Guilt, Network affiliate, BED, National Eating Disorders Association, Eating disorder, Diagnosis, Blame, Dietary supplement

MIAMI, Feb. 13, 2024 /PRNewswire/ -- Nearly 29 million Americans will experience an eating disorder in their lifetime, and only one in 10 will get the care they need. Eating Disorders Awareness Week, Feb. 26 – March 3, aims to raise awareness about eating disorders and support those affected by them. Monte Nido & Affiliates, one of the largest and leading eating disorder treatment providers in the country, provides vital treatment and resources for those who may be struggling with an eating disorder themselves or have concerns about a loved one.

Key Points: 
  • Eating Disorders Awareness Week, Feb. 26 – March 3, aims to raise awareness about eating disorders and support those affected by them.
  • Monte Nido & Affiliates , one of the largest and leading eating disorder treatment providers in the country, provides vital treatment and resources for those who may be struggling with an eating disorder themselves or have concerns about a loved one.
  • "This year, we are focused on driving awareness of binge eating disorder, which remains relatively unknown despite affecting millions of Americans.
  • Binge eating disorder (BED) is the most common eating disorder in the U.S., affecting more people than anorexia and bulimia combined.

The Emily Program Announces Residential Treatment Expansion to Adults in Columbus, Ohio

Retrieved on: 
수요일, 1월 17, 2024
Mortality, Senior counsel, CBT, Health, Eating, DBT, FBT, Dialectical behavior therapy, Binge eating disorder, PHP, Argyreia nervosa, IOP, Eating disorder, Opioid use disorder, Residential treatment center, Yoga, Physician, Residential care

COLUMBUS, Ohio, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The Emily Program, a renowned leader in eating disorder treatment , is now accepting clients into its residential program for adults in Columbus, Ohio.

Key Points: 
  • COLUMBUS, Ohio, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The Emily Program, a renowned leader in eating disorder treatment , is now accepting clients into its residential program for adults in Columbus, Ohio.
  • With this expansion, The Emily Program will address the growing demand for adult residential programming in the state.
  • This expansion extends The Emily Program's residential services in the region to adolescents and adults of all genders, eating disorders including anorexia, bulimia, and binge eating disorder.
  • For additional information about The Emily Program or to inquire about treatment, please contact 1-888-364-5977 or visit emilyprogram.com.

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

Retrieved on: 
목요일, 1월 4, 2024
Migraine, Dextromethorphan/bupropion, Binge eating disorder, DSM-IV codes, NDA, Brain, MD, Therapy, Clinical trial, Solriamfetol, FOCUS, SYMPHONY, Fibromyalgia, CNS, Prescription, Central nervous system, Patient, ADHD, Narcolepsy, Somnolence, Pharmaceutical industry

“Axsome completed its first full year as a commercial company in 2023 and, during that time, our medicines reached approximately 100,000 unique patients.

Key Points: 
  • “Axsome completed its first full year as a commercial company in 2023 and, during that time, our medicines reached approximately 100,000 unique patients.
  • Auvelity® net product sales are expected to be approximately $49 million and $130 million for the fourth quarter and full year of 2023, respectively.
  • Sunosi® net product revenue is expected to be $22 million and $74 million for the fourth quarter and full year of 2023, respectively.
  • Net product revenue excludes $66 million in license revenue recognized by Axsome in the first quarter of 2023.

Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting

Retrieved on: 
월요일, 12월 11, 2023
Long COVID, Hydrogen chloride, Long, Upsher-Smith Laboratories, Failure, National academy, Infection, Breakthrough therapy, NIAID, Binge eating disorder, Government, Research, Psychiatry, Sumatriptan, FDA, Pain, Prader–Willi syndrome, Cancer, CD40L, Orphan drug, Tonix Pharmaceuticals, Social anxiety disorder, Risk, COVID-19, Disease, Smallpox, CNS, Fibromyalgia, Obesity, Neurology, NIH, Central nervous system, Therapy, Security (finance), Annual report, Autoimmunity, Pharmaceutical industry

Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m.

Key Points: 
  • Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m.
  • A webcast of the meeting can be found here and will be available under the IR Events tab of the Tonix website at www.tonixpharma.com following the presentation.
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

Retrieved on: 
목요일, 12월 7, 2023
Sleep medicine, Psychiatry, Attention deficit hyperactivity disorder, Obstructive sleep apnea, Eastern Time Zone, Division, Binge eating disorder, TAAR1, Psychopharmacology, BED, SHARP, Medical school, DSM-IV codes, MD, Doctor of Philosophy, Research, Therapy, University, HOPE, Associate, EDS, CNS, Narcolepsy, OSA, Webcast, Central nervous system, MDD, Patient, ADHD, Harvard Medical School, Dopamine, SWD

At the event, invited physician thought leaders will discuss current and potential future indications.

Key Points: 
  • At the event, invited physician thought leaders will discuss current and potential future indications.
  • The Axsome senior leadership team will provide an overview of clinical development plans.
  • Expert thought leaders presenting at the event include:
    Craig Chepke, MD, Medical Director of Excel Psychiatric Associates in Huntersville, N.C. and Adjunct Associate Professor of Psychiatry for Atrium Health.
  • A replay of the webcast will be available for approximately 30 days following the live event.